TheracosBio and BAMCO Africa Forge Innovative Partnership
In an effort to make diabetes management more accessible, TheracosBio and BAMCO Africa have announced their partnership to introduce BRENZAVVY, an FDA-approved oral medication specifically designed to aid patients with type 2 diabetes in Sub-Saharan Africa. This collaboration highlights their mutual commitment to improving healthcare access and ensuring that patients receive the essential treatments they need.
Why This Partnership Matters
The healthcare landscape in Sub-Saharan Africa is fraught with challenges, particularly in the management of chronic diseases such as diabetes. TheracosBio has a proven track record of developing affordable therapeutics, and BAMCO Africa is dedicated to providing innovative healthcare solutions. CEO Brian Connelly of TheracosBio shared, “Our mission centers on delivering effective treatments at prices accessible to patients. Working with BAMCO allows us to extend our reach and make a real difference in the lives of individuals with type 2 diabetes.”
Understanding BRENZAVVY
BRENZAVVY (bexagliflozin) is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. It operates by enhancing the excretion of glucose through urine, effectively lowering blood sugar levels. The medication is indicated for adults diagnosed with type 2 diabetes and can be taken once daily with or without food. Research indicates that this treatment can significantly lower hemoglobin A1c levels and improve blood sugar control after just 24 weeks of use.
Shared Goals and Experience
Both TheracosBio and BAMCO Africa are driven by a shared mission: to ensure that all patients have timely access to the latest innovations in healthcare. BAMCO is recognized for its strong leadership and extensive expertise in the region, making them an ideal partner for TheracosBio. Markus Gemuend, CEO of BAMCO Africa, stated, "We are enthusiastic about launching BRENZAVVY in collaboration with TheracosBio, aiming to address the escalating health concerns related to type 2 diabetes.”
Commitment to Patient Safety
TheracosBio places significant emphasis on patient safety and therapy effectiveness. BRENZAVVY is designed for individuals whose estimated glomerular filtration rate (eGFR) is 30 mL/min/1.73 m² or higher. It’s important for healthcare providers to monitor their patients closely, particularly those with existing kidney issues or other health complicated conditions.
Supporting Sustainable Healthcare Solutions
Both companies are committed to the long-term societal impacts that this partnership will foster. By prioritizing oncology and cardio-metabolic diseases, BAMCO engages closely with local governments to tackle healthcare challenges unique to Sub-Saharan Africa. Their methods include co-creating sustainable solutions and enhancing medical education, ensuring that healthcare practitioners are well-equipped to manage the growing diabetes epidemic.
Frequently Asked Questions
What is BRENZAVVY?
BRENZAVVY is an FDA-approved oral medication that helps manage blood sugar levels in adults with type 2 diabetes.
Why is this partnership important for Sub-Saharan Africa?
This partnership brings affordable and effective diabetes treatment options to a region where access to healthcare is limited, addressing a crucial health need.
How is BRENZAVVY taken?
BRENZAVVY is taken as a 20 mg oral tablet once daily, with or without food, providing convenience for patients.
What are the potential side effects of BRENZAVVY?
Common side effects include urinary tract infections and genital mycotic infections, but residents should discuss any concerns with their healthcare providers.
How does TheracosBio aim to make treatments affordable?
TheracosBio develops innovative therapies at lower costs, ensuring broader access for patients who need them the most, thus fulfilling their mission to expand healthcare accessibility.
